Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Stifel Reiterates Buy Rating on Oruka Therapeutics (ORKA)

March 7, 2025 7:41 AM EST

Stifel analyst Alex Thompson reiterated a Buy rating and $49.00 price target on Oruka Therapeutics (NASDAQ: ORKA)

The analyst comments "We are reiterating our Buy rating following ORKA's 4Q24 update. We think ORKA is well-positioned to drive continued innovation in the psoriasis market (and beyond)... More